Abstracts tagged "Inflammation"

Abstract Number: 1625 • ACR Convergence 2025
Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
Ashika Ajitumar¹, Eric Robbins², Yusuf Mastoor² and Marcela ferrada³, ¹University of Maryland, baltimore, MD, ²University of Maryland, baltimore, ³University of Maryland, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disease marked by episodic inflammation of cartilaginous tissues. A major challenge in its clinical management is the…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 0944 • ACR Convergence 2025
L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis
Dayvia Russell¹, Soroush Moradi², Suganya Subramanian², Silvia Vaena², Sandra Mungaray², Stanley Hoffman², Stefano Berto² and Jim Oates², ¹Ralph H. Johnson VA, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease of endothelial (EC) dysfunction. We hypothesize that much of this dysfunction stems from uncoupling of endothelial nitric…
Abstract Number: 0869 • ACR Convergence 2025
PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice
Clement Adedeji¹, Muhammad Hamdan¹, Hong-Jai Park², Kelsey Wang¹ and Sang Kim³, ¹Yale University, New Haven, ²Yale University, New Haven, CT, ³Yale University, Branford, CT
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events, including inflammatory arthritis (ICI-arthritis). The pathophysiology of ICI-arthritis, particularly the role of T…
Abstract Number: 0276 • ACR Convergence 2025
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Thomas Pelowitz, Benjamin Hur, Kenneth Warrington, Jaeyun Sung and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease of the retroperitoneum that can lead to obstructive uropathy and other life-threatening complications. While RPF can…
Abstract Number: 0082 • ACR Convergence 2025
IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
Abstract Number: 2286 • ACR Convergence 2025
Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
Faissal Stipho¹, Yazin Hindosh², Jonathan Sayegh², Akram Hindosh², Bassam Mitri² and Issa Batarseh¹, ¹Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ, ²University of Arizona College of Medicine Tucson, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disorder that results in immune dysfunction and swelling of major joints, leading to discomfort, pain, stiffness, and loss…
Abstract Number: 1910 • ACR Convergence 2025
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Julie Mouchet¹, Tim Nguyen², Valeria Jordan M.³, G S Ramakrishna⁴, Linda Grinnell-Merrick², Andrew Heaney⁵, Anushka Mitra Das⁵, Pooja Shah⁶ and Evi Zhuleku⁷, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁴Novartis Healthcare Private Limited, Hyderabad, India, ⁵Novartis Ireland Ltd, Dublin, Ireland, ⁶Cytel Inc, Cambridge, ON, Canada, ⁷Cytel Inc, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions which predominantly affect individuals over the age of 50 years. The conditions…
Abstract Number: 1624 • ACR Convergence 2025
Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells
Luciana Yamamoto de Almeida¹, Kaitlin Quinn², James Simone², Lily Dai², Benjamin Turturice², Urvashi Kaundal², Chloe Palmer², Karyssa Stonick³, davide Randazzo⁴, Carmelo Carmona-Rivera⁵ and Peter Grayson⁶, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Takayasu's arteritis (TAK) is a rare, systemic, chronic large vessel vasculitis of unknown etiology primarily affecting the aorta and its branches. Arterial damage, with…
Abstract Number: 1147 • ACR Convergence 2025
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Akhila Arya Perumangote Vasudevan¹, Vishnu Mulavini², Rasiya Hashim³, Madhumitha Rondla⁴ and Dileep C Unnikrishnan⁵, ¹Yale University/Bridgeport Hospital, Stratford, CT, ²Calicut Medical College, Stratford, ³Franciscan Health Olympia & Chicago Heights, [email protected], IL, ⁴Texas tech university health sciences center, El paso, El Paso, TX, ⁵Bridgeport Hospital, Stratford, CT
Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
Abstract Number: 0931 • ACR Convergence 2025
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Salvador Campos¹, Sergio Aguilera², Juan Gutiérrez¹, Isabel Castro³, Patricia Carvajal³, Lorena Carvajal¹, Sergio González⁴, Claudio Molina⁵, María-Julieta González⁶ and María-José Barrera⁵, ¹Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ²Clinica Indisa, Santiago, Region Metropolitana, Chile, ³Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, ⁴Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, ⁵Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ⁶ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
Abstract Number: 0836 • ACR Convergence 2025
Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Aaron Baraff², Christian Lood³, Punyasha Roul⁴, Bryant England⁵, Beth Wallace⁶, Grant Cannon⁷, Gary Kunkel⁸, Ted Mikuls⁵, Patti Katz⁹, Dolores Shoback¹⁰, Jose Garcia¹¹, Ariela Orkaby¹², Joshua Baker¹³ and Tate Johnson⁵, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³University of Washington, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁹UCSF, San Rafael, CA, ¹⁰San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹²VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: RA is associated with premature aging and frailty. Growth differentiation factor-15 (GDF-15) is a biomarker that increases in response to cellular stress and inflammation…
Abstract Number: 0277 • ACR Convergence 2025
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Vaibhav Mundra¹, Cunjing Yu², Roland Morley¹, Yuan Yuan³, Yifan Qin³, Jingjing Schneider¹, Shengnan Chen³, Zhenyuan Zhou³ and Zhen Yao², ¹BeOne Medicines USA, Inc., San Carlos, CA, ²BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), ³BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)
Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
Abstract Number: 0080 • ACR Convergence 2025
The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis
Hanna Lee¹, Youn-Kwan Jung², Sang-il Lee³, Yun-Hong Cheon⁴ and Hyunjin Lim⁴, ¹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Changwon, Changwon-si, Kyongsang-namdo, Republic of Korea, ²Institute of Medical Science, Gyeongsang National University, Jinju, Jinju, Kyongsang-namdo, Republic of Korea, ³Department of Internal Medicine and Institute of Medical Science, College of Medicine, Gyeongsang National University and Hospital, Jinju, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Jinju, Kyongsang-namdo, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation, cartilage destruction, and bone erosion. Among the various immune cells involved…
Abstract Number: 2196 • ACR Convergence 2025
Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Jenny Solomon¹, Julie Piccione¹, Julie Nusbaum², Steven Carsons³ and Gregg Blumberg¹, ¹NYU Langone Long Island, Mineola, ²NYU Langone Health, New York, NY, ³NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare benign inflammatory condition of the breast usually affecting women of childbearing age with a history of breastfeeding.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].